Showing 23,074 news articles about PEP

Filters Content type: Editors' picks Topic: PEP

Post-exposure prophylaxis involves taking a 28-day course of anti-HIV drugs, after possible exposure to HIV. It may be used by healthcare workers (occupational PEP) or after sex (post-exposure prophylaxis after sexual exposure, PEPSE, also known as non-occupational PEP or nPEP).

Global health initiatives

'We're not seeing a rebound': New data shows HIV services not recovering

Editor's pick
Devex (requires free registration)
9 June 2026
New & experimental HIV treatments

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

Editor's pick
Gilead Sciences press release
9 June 2026
Human rights

Defending HIV and health services and human rights in Cameroon

Editor's pick
Frontline AIDS
9 June 2026
Government, leadership & policy

Plunging HIV Budgets Cast Dark Shadow Over UN High-Level Meeting

Editor's pick
Health Policy Watch
11 June 2026
Sexually transmitted infections prevention

UKHSA continues to recommend 4CMenB vaccine against gonorrhea in gay men

Editor's pick
i-Base
11 June 2026
Global health initiatives

Can the new UN political declaration get the HIV response back on track?

Editor's pick
Devex (requires free registration)
11 June 2026
Government, leadership & policy

HIV Response Faces ‘Biggest Storm’ in Its History After 23% Funding Nosedive

Editor's pick
Health Policy Watch
15 June 2026
Viral load

Consensus guidelines on persistent low-level viral load in people living with HIV (2026)

Editor's pick
i-Base
15 June 2026
Government, leadership & policy

Inside Trump’s Reversal on HIV

Editor's pick
POLITICO
15 June 2026
Health problems & ageing

CMV May Be a Modifiable Driver of Inflammation and Aging in People With HIV

Editor's pick
TheBodyPro
17 June 2026
PrEP science

U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

Editor's pick
Gilead Sciences press release
17 June 2026
Drug policy & policing

“It’s Authoritarian”—Harm Reduction Under San Francisco’s Backlash

Editor's pick
Filter
17 June 2026
The biology of HIV transmission

Treating elephantiasis cuts HIV risk in Tanzania

Editor's pick
SciDev.Net
17 June 2026
Epidemiology

How wastewater could spot hidden HIV burden in communities before clinics do

Editor's pick
Medical Xpress
17 June 2026
HIV treatment for children & young people

ViiV Healthcare advances paediatric HIV regulatory submissions with FDA  Priority  Review for Tivicay PD and  EMA  validation  of marketing application  for  Tivicay 

Editor's pick
ViiV Healthcare press release
22 June 2026
Government, leadership & policy

Africa can end Aids on its own terms. Will the world back us to finish the job?

Editor's pick
The Guardian
22 June 2026
Injectable & long-acting PrEP

MSF launches global campaign demanding Gilead supply HIV prevention drug for $40 a year, everywhere

Editor's pick
MSF
22 June 2026
Access to healthcare

US: HIV Clinicians Say Federal Assaults Are Making Their Patients Fall Out of Care

Editor's pick
TheBody
22 June 2026
Injectable & long-acting PrEP

Is Kenya’s lenacapavir rollout missing young women and girls?

Editor's pick
Devex (requires free registration)
22 June 2026
Global health initiatives

New Plan Scales Back C.D.C.’s Work on Diseases Abroad

Editor's pick
The New York Times (requires free registration)
22 June 2026
Global health initiatives

US to stop funding HIV programmes in South Africa

Editor's pick
BBC News
22 June 2026
Activism & civil society

‘A matter of life or death’: the activists confronting US Congress about slashing HIV funding

Editor's pick
The Guardian
23 June 2026
Injectable & long-acting PrEP

Closer to home: taking long-acting HIV prevention into Zambia’s communities

Editor's pick
Unitaid
24 June 2026
Government, leadership & policy

US and Russia Vote Against UN Political Declaration on HIV/ AIDS

Editor's pick
Health Policy Watch
24 June 2026